Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Mar 1;181(3):317-328.
doi: 10.1001/jamainternmed.2020.7090.

Effectiveness of Mindfulness Meditation vs Headache Education for Adults With Migraine: A Randomized Clinical Trial

Affiliations
Randomized Controlled Trial

Effectiveness of Mindfulness Meditation vs Headache Education for Adults With Migraine: A Randomized Clinical Trial

Rebecca Erwin Wells et al. JAMA Intern Med. .

Abstract

Importance: Migraine is the second leading cause of disability worldwide. Most patients with migraine discontinue medications due to inefficacy or adverse effects. Mindfulness-based stress reduction (MBSR) may provide benefit.

Objective: To determine if MBSR improves migraine outcomes and affective/cognitive processes compared with headache education.

Design, setting, and participants: This randomized clinical trial of MBSR vs headache education included 89 adults who experienced between 4 and 20 migraine days per month. There was blinding of participants (to active vs comparator group assignments) and principal investigators/data analysts (to group assignment).

Interventions: Participants underwent MBSR (standardized training in mindfulness/yoga) or headache education (migraine information) delivered in groups that met for 2 hours each week for 8 weeks.

Main outcomes and measures: The primary outcome was change in migraine day frequency (baseline to 12 weeks). Secondary outcomes were changes in disability, quality of life, self-efficacy, pain catastrophizing, depression scores, and experimentally induced pain intensity and unpleasantness (baseline to 12, 24, and 36 weeks).

Results: Most participants were female (n = 82, 92%), with a mean (SD) age of 43.9 (13.0) years, and had a mean (SD) of 7.3 (2.7) migraine days per month and high disability (Headache Impact Test-6: 63.5 [5.7]), attended class (median attendance, 7 of 8 classes), and followed up through 36 weeks (33 of 45 [73%] of the MBSR group and 32 of 44 [73%] of the headache education group). Participants in both groups had fewer migraine days at 12 weeks (MBSR: -1.6 migraine days per month; 95% CI, -0.7 to -2.5; headache education: -2.0 migraine days per month; 95% CI, -1.1 to -2.9), without group differences (P = .50). Compared with those who participated in headache education, those who participated in MBSR had improvements from baseline at all follow-up time points (reported in terms of point estimates of effect differences between groups) on measures of disability (5.92; 95% CI, 2.8-9.0; P < .001), quality of life (5.1; 95% CI, 1.2-8.9; P = .01), self-efficacy (8.2; 95% CI, 0.3-16.1; P = .04), pain catastrophizing (5.8; 95% CI, 2.9-8.8; P < .001), depression scores (1.6; 95% CI, 0.4-2.7; P = .008), and decreased experimentally induced pain intensity and unpleasantness (MBSR group: 36.3% [95% CI, 12.3% to 60.3%] decrease in intensity and 30.4% [95% CI, 9.9% to 49.4%] decrease in unpleasantness; headache education group: 13.5% [95% CI, -9.9% to 36.8%] increase in intensity and an 11.2% [95% CI, -8.9% to 31.2%] increase in unpleasantness; P = .004 for intensity and .005 for unpleasantness, at 36 weeks). One reported adverse event was deemed unrelated to study protocol.

Conclusions and relevance: Mindfulness-based stress reduction did not improve migraine frequency more than headache education, as both groups had similar decreases; however, MBSR improved disability, quality of life, self-efficacy, pain catastrophizing, and depression out to 36 weeks, with decreased experimentally induced pain suggesting a potential shift in pain appraisal. In conclusion, MBSR may help treat total migraine burden, but a larger, more definitive study is needed to further investigate these results.

Trial registration: ClinicalTrials.gov Identifier: NCT02695498.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Drs Wells and Zeidan reported grants from the National Institutes of Health during the conduct of the study. Dr Houle reported personal fees from GlaxoSmithKline, Eli Lilly, and StatReviewer outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Overview of Study Design, Conducted for Each Cohort
MBSR indicates mindfulness-based stress reduction. aTrained study team members conducted the phone screens, including the principal investigator, master’s-level students, and undergraduate students. bParticipants were initially required to be migraine-free for 48 hours prior to each study visit, but to complete the study, this was changed (after cohort 1’s 12-week study visit) to migraine-free the day of study visits (given that participants’ headache frequencies could be up to 20 days per month). See details in Supplement 2. cQuestionnaires were completed in-person at the screening visit and in-person or remotely for follow-up visits (when headache-free). dAll quantitative sensory testing (QST) assessments were in-person, with confirmation of no pain relieving medications taken within 12 hours. eThis run-in period confirmed ability to maintain daily headache log and confirmed eligibility criteria (assessment of migraine frequency and exclusion for medication overuse headache). fQualitative interview results will be reported elsewhere.
Figure 2.
Figure 2.. CONSORT Flow Diagram of Study Participation
See eTable 5 and eTable 6 in Supplement 1 for details of reasons and time points for exclusion, withdrawal, and lost to follow-up.
Figure 3.
Figure 3.. Changes in Well-Being and Experimental Pain Intensity and Unpleasantness Between Mindfulness-Based Stress Reduction (MBSR) and Headache Education
FFM indicates Five Facet Mindfulness; GAD-7, Generalized Anxiety Disorder 7; HIT-6, Headache Impact Test; HMSE, Headache Management Self-Efficacy; MIDAS, Migraine Disability Assessment, one month; MSQv2.1, Migraine Specific Quality of Life; PCS, Pain Catastrophizing Scale; PHQ-9, Patient Health Questionnaire-9 Depression. A, Point estimates of Cohen d effect size differences between treatment groups with 95% CIs, with positive directional effect indicating an improvement in MBSR relative to headache education for each measure. HIT-6 displayed at 3 time points due to a significant treatment-visit interaction. All other instrument treatment effect measures did not significantly differ across visits (P > .05). Cohen d effect sizes of 0.2 are considered small, 0.5 medium, 0.8 large, and 1.2 very large., B, Experimental pain measured with quantitative sensory testing, with visual analog scale range of 0-10.

Comment in

Similar articles

Cited by

References

    1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators . Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789-1858. doi:10.1016/S0140-6736(18)32279-7 - DOI - PMC - PubMed
    1. Archibald N, Lipscomb J, McCrory DC. Resource Utilization and Costs of Care for Treatment of Chronic Headache. In: AHRQ Technical Reviews and Summaries. US Agency for Health Care Policy and Research; 1999. - PubMed
    1. Lipton RB, Hutchinson S, Ailani J, et al. . Discontinuation of acute prescription medication for migraine: results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Headache. 2019;59(10):1762-1772. - PMC - PubMed
    1. Loder E, Weizenbaum E, Frishberg B, Silberstein S; American Headache Society Choosing Wisely Task Force . Choosing wisely in headache medicine: the American Headache Society’s list of five things physicians and patients should question. Headache. 2013;53(10):1651-1659. doi:10.1111/head.12233 - DOI - PubMed
    1. Burch RC, Buse DC, Lipton RB. Migraine: epidemiology, burden, and comorbidity. Neurol Clin. 2019;37(4):631-649. doi:10.1016/j.ncl.2019.06.001 - DOI - PubMed

Publication types

Associated data